TOP TEN perturbations for 1552283_s_at (Homo sapiens)

Organism: Homo sapiens
Gene: 1552283_s_at
Selected probe(set): 232417_x_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 1552283_s_at (232417_x_at) across 6672 perturbations tested by GENEVESTIGATOR:

atopic dermatitis study 21 (lesional; whole skin) / normal skin tissue

Relative Expression (log2-ratio):-2.3774767
Number of Samples:5 / 6
Experimental atopic dermatitis study 21 (lesional; whole skin)
Lesional full thickness skin samples isolated from patient with moderate-to-severe atopic dermatitis by laser capture microdissection. Patients' cohort characteristics: 3 males and 2 females; age 27-59 years (mean age: 39.4 years); SCORing of Atopic Dermatitis index (SCORAD) ranging from 45-65; total IgE: 14-1821 kU/l; eosinophilic count: 1.4-11.8 %.
Control normal skin tissue
Full thickness skin samples isolated from healthy subjects by laser capture microdissection.

colorectal cancer study 43 (metastase; brain) / colorectal cancer study 43 (metastase; lung)

Relative Expression (log2-ratio):2.2138214
Number of Samples:2 / 5
Experimental colorectal cancer study 43 (metastase; brain)
Metastatic tumor tissue obtained from the brain of patients with primary colorectal adenocarcinoma.
Control colorectal cancer study 43 (metastase; lung)
Metastatic tumor tissue obtained from the lung of patients with primary colon adenocarcinoma.

cutaneous T-cell lymphoma study 1 (tumor phase) / normal skin tissue

Relative Expression (log2-ratio):-2.1916685
Number of Samples:4 / 8
Experimental cutaneous T-cell lymphoma study 1 (tumor phase)
Lesional skin biopsies from patients with cutaneous T-cell lymphoma in the tumor phase (extranodal).
Control normal skin tissue
Skin biopsies from healthy individuals.

psoriasis study 11 (lesional; brodalumab; 15d; 700mg) / psoriasis study 11 (lesional; baseline)

Relative Expression (log2-ratio):1.7758999
Number of Samples:8 / 25
Experimental psoriasis study 11 (lesional; brodalumab; 15d; 700mg)
Lesional skin punch biopsies derived from patients with moderate to severe plaque psoriasis at day 15 (week 2) after treatment with a single dose (700 mg i.v.) of brodalumab. ATC code:
Control psoriasis study 11 (lesional; baseline)
Lesional skin punch biopsy samples derived from patients with moderate to severe plaque psoriasis before treatment.

ovarian tumor study 11 (low grade) / normal ovarian surface epithelial cell sample

Relative Expression (log2-ratio):1.7500916
Number of Samples:11 / 6
Experimental ovarian tumor study 11 (low grade)
Human microdissected tumor cells from the ovary of patients with low grade serous carcinoma.
Control normal ovarian surface epithelial cell sample
Human microdissected ovarian surface epithelial cell sample from the ovary of healthy individuals.

atopic dermatitis study 21 (non-lesional; whole skin) / normal skin tissue

Relative Expression (log2-ratio):-1.7423115
Number of Samples:5 / 6
Experimental atopic dermatitis study 21 (non-lesional; whole skin)
Non-lesional full thickness skin samples isolated from patient with moderate-to-severe atopic dermatitis by laser capture microdissection. Patients' cohort characteristics: 3 males and 2 females; age 27-59 years (mean age: 39.4 years); SCORing of Atopic Dermatitis index (SCORAD) ranging from 45-65; total IgE: 14-1821 kU/l; eosinophilic count: 1.4-11.8 %.
Control normal skin tissue
Full thickness skin samples isolated from healthy subjects by laser capture microdissection.

cutaneous T-cell lymphoma study 1 (plaque phase) / normal skin tissue

Relative Expression (log2-ratio):-1.7382774
Number of Samples:7 / 8
Experimental cutaneous T-cell lymphoma study 1 (plaque phase)
Lesional skin biopsies from patients with cutaneous T-cell lymphoma in the plaque phase.
Control normal skin tissue
Skin biopsies from healthy individuals.

CH5183284 study 1 (HSC-39) / vehicle (DMSO) treated HSC-39 cell sample

Relative Expression (log2-ratio):1.7287693
Number of Samples:2 / 2
Experimental CH5183284 study 1 (HSC-39)
Human gastric cell line HSC-39 treated with 1 uM of FGFR inhibitor CH5183284 for 24 hours. ATC code:---
Control vehicle (DMSO) treated HSC-39 cell sample
Human gastric cell line HSC-39 treated with 0.1% DMSO for 24 hours.

colorectal cancer study 43 (metastase; brain) / colorectal cancer study 43 (metastase; liver)

Relative Expression (log2-ratio):1.7241335
Number of Samples:2 / 25
Experimental colorectal cancer study 43 (metastase; brain)
Metastatic tumor tissue obtained from the brain of patients with primary colorectal adenocarcinoma.
Control colorectal cancer study 43 (metastase; liver)
Metastatic tumor tissue obtained from the liver of patients with primary colon adenocarcinoma.

breast cancer study 42 (metastase; liver) / breast cancer study 42 (metastase; chest wall)

Relative Expression (log2-ratio):1.6414642
Number of Samples:3 / 2
Experimental breast cancer study 42 (metastase; liver)
Metastatic tumor tissue obtained from the liver of patients with primary breast adenocarcinoma.
Control breast cancer study 42 (metastase; chest wall)
Metastatic tumor tissue obtained from the chest wall of patients with primary breast adenocarcinoma.

Organism: Homo sapiens
Gene: 1552283_s_at
Selected probe(set): 221646_s_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 1552283_s_at (221646_s_at) across 6672 perturbations tested by GENEVESTIGATOR:

Langerhans cell histiocytosis study 2 (multisystem) / normal epidermal Langerhans cell sample

Relative Expression (log2-ratio):-4.75305
Number of Samples:2 / 10
Experimental Langerhans cell histiocytosis study 2 (multisystem)
Langerhans cell histiocytes (LCH, CD207+) samples isolated from LCH lesions of patients with multifocal, multisystem (disseminated) disease. Both patients received chemotherapy. Sites of LCH lesions: subj.ID:1 (skin, lungs, multiple skull, mastoid, gingiva), subj.ID:13 (mandible, skull, vertebrae, recurrent orbit, liver, spleen, pituitary gland).
Control normal epidermal Langerhans cell sample
Normal epidermal Langerhans cells (CD207+) were isolated from skin of children donors (age < 18 years). The Langerhans cells were isolated from presumably healthy tissue.

colorectal cancer study 43 (metastase; brain) / colorectal cancer study 43 (metastase; lung)

Relative Expression (log2-ratio):3.919385
Number of Samples:2 / 5
Experimental colorectal cancer study 43 (metastase; brain)
Metastatic tumor tissue obtained from the brain of patients with primary colorectal adenocarcinoma.
Control colorectal cancer study 43 (metastase; lung)
Metastatic tumor tissue obtained from the lung of patients with primary colon adenocarcinoma.

Langerhans cell histiocytosis study 2 (unifocal) / normal epidermal Langerhans cell sample

Relative Expression (log2-ratio):-3.8521557
Number of Samples:8 / 10
Experimental Langerhans cell histiocytosis study 2 (unifocal)
Langerhans cell histiocytes (LCH, CD207+) samples isolated from LCH lesions of patients with unifocal, single system disease (bone lesion).
Control normal epidermal Langerhans cell sample
Normal epidermal Langerhans cells (CD207+) were isolated from skin of children donors (age < 18 years). The Langerhans cells were isolated from presumably healthy tissue.

connective/soft tissue cancer study 1 (PDX; connective and soft tissue, synovial sarcoma, spindle cell; primary) / connective/soft tissue cancer study 1 (PDX; connective and soft tissue, liposarcoma, well differentiated type; primary)

Relative Expression (log2-ratio):3.801793
Number of Samples:6 / 2
Experimental connective/soft tissue cancer study 1 (PDX; connective and soft tissue, synovial sarcoma, spindle cell; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary connective and soft tissue, synovial sarcoma, spindle cell of the soft tissue (subcutaneously implanted).
Control connective/soft tissue cancer study 1 (PDX; connective and soft tissue, liposarcoma, well differentiated type; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary connective and soft tissue, liposarcoma, well differentiated type of the soft tissue (subcutaneously implanted).

connective/soft tissue cancer study 1 (PDX; connective and soft tissue, synovial sarcoma, spindle cell; primary) / connective/soft tissue cancer study 1 (PDX; connective and soft tissue, dedifferentiated liposarcoma; primary)

Relative Expression (log2-ratio):3.8017778
Number of Samples:6 / 5
Experimental connective/soft tissue cancer study 1 (PDX; connective and soft tissue, synovial sarcoma, spindle cell; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary connective and soft tissue, synovial sarcoma, spindle cell of the soft tissue (subcutaneously implanted).
Control connective/soft tissue cancer study 1 (PDX; connective and soft tissue, dedifferentiated liposarcoma; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary connective and soft tissue, dedifferentiated liposarcoma of the soft tissue (subcutaneously implanted).

connective/soft tissue cancer study 1 (PDX; connective and soft tissue, synovial sarcoma, spindle cell; primary) / connective/soft tissue cancer study 1 (PDX; connective and soft tissue, leiomyosarcoma, NOS; primary)

Relative Expression (log2-ratio):3.603629
Number of Samples:6 / 2
Experimental connective/soft tissue cancer study 1 (PDX; connective and soft tissue, synovial sarcoma, spindle cell; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary connective and soft tissue, synovial sarcoma, spindle cell of the soft tissue (subcutaneously implanted).
Control connective/soft tissue cancer study 1 (PDX; connective and soft tissue, leiomyosarcoma, NOS; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary connective and soft tissue, leiomyosarcoma, NOS of the soft tissue (subcutaneously implanted).

connective/soft tissue cancer study 1 (PDX; connective and soft tissue, synovial sarcoma, spindle cell; primary) / connective/soft tissue cancer study 1 (PDX; connective and soft tissue, pleomorphic rhabdomyosarcoma, adult type; primary)

Relative Expression (log2-ratio):3.5709343
Number of Samples:6 / 2
Experimental connective/soft tissue cancer study 1 (PDX; connective and soft tissue, synovial sarcoma, spindle cell; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary connective and soft tissue, synovial sarcoma, spindle cell of the soft tissue (subcutaneously implanted).
Control connective/soft tissue cancer study 1 (PDX; connective and soft tissue, pleomorphic rhabdomyosarcoma, adult type; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary connective and soft tissue, pleomorphic rhabdomyosarcoma, adult type of the soft tissue (subcutaneously implanted).

atopic dermatitis study 21 (lesional; epidermis) / normal epidermis tissue

Relative Expression (log2-ratio):-3.4790373
Number of Samples:5 / 10
Experimental atopic dermatitis study 21 (lesional; epidermis)
Lesional epidermal samples isolated from patient with moderate-to-severe chronic atopic dermatitis by laser capture microdissection. Patients' cohort characteristics: 3 males and 2 females; age 27-59 years (mean age: 39.4 years); SCORing of Atopic Dermatitis index (SCORAD) ranging from 45-65; total IgE: 14-1821 kU/l; eosinophilic count: 1.4-11.8 %.
Control normal epidermis tissue
Epidermal samples isolated from healthy subjects by laser capture microdissection.

B-CLL study 11 (DMSO) / vehicle (DMSO) treated normal T-cell sample

Relative Expression (log2-ratio):-3.3447227
Number of Samples:4 / 4
Experimental B-CLL study 11 (DMSO)
Peripheral blood mononuclear cells (PBMCs) obtained from chronic lymphocytic leukemia (CLL) patients and in vitro treated with vehicle (DMSO) for 4 hours. PBMCs’ samples contained 90% CD19+ CD5+ B lineage CLL cells (B-CLL). Inclusion criteria: untreated CLL patients or at least 1 month after chemotherapy. Exclusion criteria: patients with active infections or other serious medical conditions or with white blood cell (WBC) counts of 15,000/l.
Control vehicle (DMSO) treated normal T-cell sample
MACS purified T-cells from healthy donor peripheral blood treated with vehicle (DMSO) for 4 hours.

ovarian tumor study 30 (PDX; carcinoma, NOS; metastatic) / ovarian tumor study 30 (PDX; adenocarcinoma, NOS; primary)

Relative Expression (log2-ratio):3.3398209
Number of Samples:2 / 2
Experimental ovarian tumor study 30 (PDX; carcinoma, NOS; metastatic)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from a metastasis of patients with primary carcinoma, NOS of the ovary (subcutaneously implanted). Metastatic site of patient tumor sample is not reported.
Control ovarian tumor study 30 (PDX; adenocarcinoma, NOS; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary adenocarcinoma, NOS of the ovary (subcutaneously implanted).